When will HARMONi-3 read out?
Following Summit Therapeutics’ November 15, 2026 (U.S. time) announcement of an FDA complete response letter for Akeso’s ivonescimab, HARMONi-3 remains a separate first-line lung cancer trial. Summit’s November 4, 2026 guidance expected squamous-cohort primary progression-free survival and early interim overall survival analyses in Q4 2026, followed by non-squamous progression-free survival analysis in H1 2027. These are company expectations rather than guaranteed public readout or approval dates; HARMONi-7 separately compares ivonescimab monotherapy with pembrolizumab in first-line PD-L1-high lung cancer.
| Measure | Reported result | Basis |
|---|---|---|
| Squamous cohort | Q4 2026 | Events for primary PFS analysis |
| Squamous cohort | Q4 2026 | Early interim OS analysis alongside primary PFS analysis |
| Non-squamous cohort | H1 2027 | Events for PFS analysis |
| Timing basis | Company expectations | Event-driven; analysis timing may change |
Ivonescimab after the FDA letter
On November 15, 2026 (U.S. time), Summit Therapeutics announced that it had received an FDA complete response letter for Akeso’s ivonescimab. In the 438-patient HARMONi trial, primary overall survival yielded p=0.057 against a prespecified threshold of 0.0448; median overall survival was 16.8 months with ivonescimab plus chemotherapy versus 14.0 months with chemotherapy. The application could not be approved on the current data. Subsequent first-line lung cancer evidence will come from HARMONi-3 and HARMONi-7.
Sources
Read the full analysis
FDA Rejects Akeso’s Bispecific: PFS Was Not Enough — November 17, 2026